Close Menu

NEW YORK – OpGen announced on Wednesday a preliminary 19 percent revenue increase for 2019 to $3.5 million from $3 million in 2018.

Revenue from the company's Acuitas AMR Gene Panel and Acuitas Lighthouse increased 147 percent to approximately $1.4 million, and preliminary operating loss was approximately $12.4 million, down 7 percent from $13.4 million in 2018. OpGen said it will announce its full-year and fourth quarter financial results in March.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.